Consultant Mie Holm Vilstrup Department of Nuclear Medicine, Odense University Hospital
Projektet i tal
OPEN undersøgelse/kliniske data
Forventet # af deltagere
Inkluderet antal deltagere
Inkluderede deltagere med prøver
Dual PETOvac - Dual Time PET/CT in preoperative assessment of ovarian cancer
To compare magnetic resonance imaging (MR) versus positron emission tomography/computed tomography PET/CT) carried out 1 and 3 hours after injection of 18F-Fluorodeoxyglycose (FDG) in the preoperative evaluation of pelvic masses in ovarian cancer
Treatment of ovarian cancer involves surgery and chemotherapy. The decision of operability is made at the multidisciplinary conference. Prognosis depends not only in the stage and histological type of the tumor but also at the end result of surgery. Residual disease after initial surgery is a strong prognostic factor for survival, with improvement on both overall and progression free survival being greatest in women with no or minimal (tumor < 1 cm) visible disease at the end surgery. Supra radical surgery is a radical procedure plus e.g. extensive peritonectomy, resection of liver metastases, splenectomy, resection of the tail of pancreas and bowel resection. Only 60% of patients in advanced stage ovarian cancer are deemed optimal debulked peroperativ. Patients with optimal debulking have a 5 year survival of 42% versus patients not possible of achieve radical operation with 5 year survival of 15%, resulting in a hazard rate of 2,12 for optimal vs. not optimal debulking. A correct preoperative assessment is important in planning of operation and to avoid futile operation in patients not resectable. Theoretically, you should get increased tumor/background ratio by performing a late FDG-PET/CT scan 3 hours after injection, thus better being able to distinguish between malignant and benign.
Description of the cohort
Patients with clinical high suspicion of ovarian cancer.
Publications associated with the project
Linked Hexokinase and Glucose-6-Phosphatase Activities Reflect Grade of Ovarian Malignancy. Olsen BB, Gjedde A, Vilstrup MH, Johnsen IBG, Neumann G, Torigian DA, Alavi A, Høilund-Carlsen PF. Mol Imaging Biol. 2018 Jul 9. doi: 10.1007/s11307-018-1247-2